Research ArticleTheranostics
177Lu-3BP-227 for Neurotensin Receptor 1–Targeted Therapy of Metastatic Pancreatic Adenocarcinoma: First Clinical Results
Richard P. Baum, Aviral Singh, Christiane Schuchardt, Harshad R. Kulkarni, Ingo Klette, Stefan Wiessalla, Frank Osterkamp, Ulrich Reineke and Christiane Smerling
Journal of Nuclear Medicine May 2018, 59 (5) 809-814; DOI: https://doi.org/10.2967/jnumed.117.193847
Richard P. Baum
1Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany; and
Aviral Singh
1Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany; and
Christiane Schuchardt
1Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany; and
Harshad R. Kulkarni
1Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany; and
Ingo Klette
1Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany; and
Stefan Wiessalla
1Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany; and
Frank Osterkamp
23B Pharmaceuticals GmbH, Berlin, Germany
Ulrich Reineke
23B Pharmaceuticals GmbH, Berlin, Germany
Christiane Smerling
23B Pharmaceuticals GmbH, Berlin, Germany

Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 59, Issue 5
May 1, 2018
177Lu-3BP-227 for Neurotensin Receptor 1–Targeted Therapy of Metastatic Pancreatic Adenocarcinoma: First Clinical Results
Richard P. Baum, Aviral Singh, Christiane Schuchardt, Harshad R. Kulkarni, Ingo Klette, Stefan Wiessalla, Frank Osterkamp, Ulrich Reineke, Christiane Smerling
Journal of Nuclear Medicine May 2018, 59 (5) 809-814; DOI: 10.2967/jnumed.117.193847
177Lu-3BP-227 for Neurotensin Receptor 1–Targeted Therapy of Metastatic Pancreatic Adenocarcinoma: First Clinical Results
Richard P. Baum, Aviral Singh, Christiane Schuchardt, Harshad R. Kulkarni, Ingo Klette, Stefan Wiessalla, Frank Osterkamp, Ulrich Reineke, Christiane Smerling
Journal of Nuclear Medicine May 2018, 59 (5) 809-814; DOI: 10.2967/jnumed.117.193847
Jump to section
Related Articles
Cited By...
- Synthesis of 64Cu-, 55Co-, and 68Ga-Labeled Radiopharmaceuticals Targeting Neurotensin Receptor-1 for Theranostics: Adjusting In Vivo Distribution Using Multiamine Macrocycles
- Complexes of the neurotensin receptor 1 with small-molecule ligands reveal structural determinants of full, partial, and inverse agonism
- Theranostics: Leveraging Molecular Imaging and Therapy to Impact Patient Management and Secure the Future of Nuclear Medicine
- Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine
- Fibroblast-Activating Protein: Targeting the Roots of the Tumor Microenvironment